Promore Pharma
STOCKHOLM, SE / ACCESSWIRE / November 19, 2021 / Promore Pharma (STO:PROMO) (FRA:8T0)
Promore Pharma AB (publ) publishes its interim report for the third quarter 2021 on 23 November 2021.
The next day, 24 November, the company will host a webcast telephone conference at 09.00 CET, with President and CEO Jonas Ekblom and CFO Erik Magnusson, where an update for the quarter and upcoming activities. After the presentation there will be a Q&A session. The conference call will be held in English and can be accessed via computer, tablet, or telephone.
The number of attendees is limited, please register for the conference in advance on the following link:
https://attendee.gotowebinar.com/register/3513796589233231628
The conference call will be recorded and made available on the company´s website after the call, and on
Västra Hamnen Corporate Finance Youtube channel.
For additional information, please contact
Jonas Ekblom, CEO
Phone: [+46] 736 777 540
E-mail: jonas.ekblom@promorepharma.com
Erik Magnusson, CFO
Phone: [+46] 708 565 245
E-mail: erik.magnusson@promorepharma.com
Promore Pharmas Certified Adviser is Erik Penser Bank
Tel: [+46] 8-463 83 00
E-mail: certifiedadviser@penser.se
Promore Pharma in brief
Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides. The company's aim is to develop first-in-category pharmaceuticals for indications with high unmet medical needs, where very few efficacious prescription pharmaceuticals are available. Promore Pharma's two projects are undergoing clinical development and have a very strong safety profile since the products are based on endogeneous substances that are administered locally. The leading project, ensereptide (PXL01), that will be used for prevention of post-surgical scarring, is being prepared for a clinical phase II-trial if the peptide can prevent the formation of unesthetical scars on the skin. Ropocamptide (LL-37) has recently been evaluated in a clinical phase IIb study with positive results in patients with venous leg ulcers (VLUs). The product candidates can also be deployed for other indications, such as preventing unfavorable tissue attachments (adhesions) after different kinds of surgical procedures and treatment of diabetic foot ulcers. The company is listed on Nasdaq First North Growth Market.
Attachments
Invitation to Conference Call regarding Promore Pharma's Interim Report for the Third Quarter 2021
SOURCE: Promore Pharma
View source version on accesswire.com:
https://www.accesswire.com/673758/Invitation-to-Conference-Call-Regarding-Promore-Pharmas-Interim-Report-for-the-Third-Quarter-2021
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
New GTDC Report Highlights Effective Methods for Building Optimal Channel Strategies2.12.2025 15:00:00 CET | Press release
TAMPA, FL / ACCESS Newswire / December 2, 2025 / The Global Technology Distribution Council (GTDC) has released a groundbreaking new industry study titled "Building the Optimal Distribution Strategy." This comprehensive guide provides insights and valuable best practices for evaluating market and channel coverage needs and determining which types of distributors provide the best fit for technology suppliers. Former global channel chief and partner route to market specialist Donna Grothjan led the development of this member-inspired GTDC project, adding her personal knowledge and experience creating and managing distribution strategies, as well as gathering and sharing insight from respected industry peers and subject matter experts. Distribution remains the most cost-effective route-to-market for technology suppliers. That value is rising rapidly in the cloud era as emerging and legacy vendors look to scale sales, support and other operations around these virtual offerings without requ
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer's and Other Neurodegenerative Diseases2.12.2025 06:00:00 CET | Press release
Phase 1 results show that SUL-238 is safe, well-tolerated, and demonstrates favorable pharmacokinetics with high CSF penetration in healthy elderly volunteers, supporting its advancement into further clinical development for Alzheimer's and other neurodegenerative diseases. ANKARA, TR / ACCESS Newswire / December 2, 2025 / GEN Pharmaceuticals (GENIL.IS), Türkiye's leading specialty pharmaceutical company, has announced new positive results from its Phase 1 clinical trial evaluating the safety, tolerability, and pharmacokinetics (PK) of first-in-class, novel orally administered mitochondria-directed drug candidate SUL-238 in healthy elderly volunteers. The findings were presented at the 18th Clinical Trials on Alzheimer's Disease (CTAD) in San Diego, CA (United States) today. SUL-238 was originally discovered by Sulfateq and has since been further developed through a collaborative effort of Sulfateq and GEN as a novel therapeutic in neurodegenerative diseases. This Phase 1 randomized, d
TheaMou by Theo Announces Global Revival of the Original Olympic Games and Operation PAME BROSTA at Athens Fashion Week26.11.2025 19:00:00 CET | Press release
TheaMou Ignites Athens Fashion Week with a Goddess-Warrior Revival Rooted in Ancient Greece ATHENS, GREECE / ACCESS Newswire / November 26, 2025 / TheaMou by Theo ("My Goddess" in Greek), the creative umbrella uniting MeaDea by Theo, Iellele by Theo, MiDiosa by Theo, and aligned cultural initiatives, presented its Ancient Greek Goddess & Warrior Collection at Athens Fashion Week on November 14th, 2025. Founder, Sam Stathis, used the Athens Fashion Week stage to officially launch operation PAME BROSTA (Moving forward in Greek) and announce the global revival of the ORIGINAL OLYMPIC GAMES.Sam Stathis with Olympic Angels at Athens Fashion Week Sam Stathis with Olympic Angels and TheaMou by MeaDea models at Athens Fashion Week Three Olympic Angels by Theo, each a crowned national beauty queen (Miss Greece-Star Hellas, Stella Mihailidou, Miss Italia, Federica Rizza, and Miss Netherlands, Elize DeJong), opened the runway show, symbolizing the revival of the True Flame of Greece through divin
Clean Air Metals Files PEA Technical Report for the Thunder Bay North Critical Minerals Project24.11.2025 13:00:00 CET | Press release
THUNDER BAY, ON / ACCESS Newswire / November 24, 2025 / Clean Air Metals Inc. ("Clean Air Metals" or the "Company") (TSXV:AIR)(FRA:CKU)(OTCQB:CLRMF) is pleased to announce that it has filed the Preliminary Economic Assessment (PEA) and updated resource that was completed for its Thunder Bay PGE-Cu-Ni Project near Thunder Bay, Ontario, Canada. The results of the PEA and resource were previously disclosed in the Company's news release dated October 9th, 2025. The PEA outlines an 11-year mine life (+ 2 years of pre-production activities) producing 2,500 tonnes per day from a near-surface, ramp-access underground operation. The report is available under the Company's profile at www.Sedarplus.ca and will be available on the Company's website at www.cleanairmetals.ca. All figures are in Canadian Dollars, unless specified otherwise. Highlights The project has a $219.4M1 pre-tax NPV8 against a project capital cost of $89.5M. After-tax NPV of $157.5M The pre-tax internal rate of return (IRR) is
Capital.com Strengthens European Operations with Expanded Customer Service Hub in Bulgaria24.11.2025 09:00:00 CET | Press release
Reports trading volumes of $744 billion in Q3 2025 SOFIA, BG / ACCESS Newswire / November 24, 2025 / Capital.com, the high-growth trading platform and fintech group, today announced the expansion of its operations in Bulgaria with the opening of a new office at Sofia's Office X Business Garden and a 51% increase in local headcount over the past year. This development aligns with the company's strategy to build specialised centres of excellence across key functions, with Bulgaria leading the way in customer service. Building on its established presence in Sofia and complementing its technology hub in Poland, Capital.com plans to invest up to €5 million into its operational infrastructure to create a centre of excellence for customer service and one of the best workplace experiences in the industry. The Bulgaria hub will set the gold standard for service quality, responsiveness, and multilingual support, playing a pivotal role in supporting clients worldwide while fostering a culture of
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom